GlassScriptPhysician profile
Jennifer Berry
NPI 1134572282
$1,408.32
in general payments reported to CMS, 2019-2025
18 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $142 · 2023: $814 · 2024: $291 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.67 | 2023-2025 | |
| Novo Nordisk INC | $134.36 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $122.17 | 2022-2024 | Mounjaro, Zepbound |
| Medtronic, INC. | $95.72 | 2025 | Concertotm |
| Bayer Healthcare Pharmaceuticals INC. | $90.90 | 2022-2023 | |
| Sanofi Pasteur INC. | $59.92 | 2023 | |
| Gilead Sciences, INC. | $51.89 | 2023-2024 | |
| Astellas Pharma US INC | $49.86 | 2023-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $42.13 | 2023 | |
| Lucid Diagnostics INC. | $37.44 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $33.06 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.25 | 2022 | |
| Currax Pharmaceuticals LLC | $28.14 | 2022-2023 | Contrave |
| Otsuka America Pharmaceutical, INC. | $22.01 | 2023 | Abilify Maintena, Rexulti |
| Nestle Healthcare Nutrition INC. | $19.50 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.41 | 2023 | Prolia, Evenity |
| Hologic Sales and Service, LLC | $17.75 | 2024 | Thinprep 2000 Processor, Aptima |
| Glaxosmithkline, LLC. | $16.14 | 2024 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.